International Finance Corporation (IFC) is planning to invest up to $75 million (around Rs 500 crore) in Glenmark Pharmaceuticals. The pharma major is aiming to raise up to $200 million through market issuance of quasi-equity instruments in order to reduce debt and expand operations, of which IFC proposes to invest up to $75 million.
The proposed investment will allow Glenmark to expand its manufacturing capacity mainly in India, to build research and development capacity for new molecules and to reduce some debt so that internal accruals can be deployed more for R&D.
Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India. It manufactures and markets generic formulation products and active pharmaceutical ingredients, both in the domestic and international markets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.60 |
| Dr. Reddys Lab | 1232.65 |
| Cipla | 1242.10 |
| Zydus Lifesciences | 944.25 |
| Lupin | 2328.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: